Taysha Gene Therapies (TSHA) Stock Statistics & Valuation Metrics

Taysha Gene Therapies has a market cap or net worth of $1.33B. The enterprise value is $2.11B.

Market Cap

$1.33B

Enterprise Value

$2.11B

Taysha Gene Therapies has 325,833,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

325,833,560

Owned by Insiders

2.88%

Owned by Institutions

22.64%

Taysha Gene Therapies’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -34.88%.

Return on Equity (ROE)

-0.44

Return on Assets (ROA)

-0.32

Return on Invested Capital (ROIC)

-34.88%

Return on Capital Employed (ROCE)

-0.35

Revenue Per Employee

98.72K

Profits Per Employee

-1.10M

Employee Count

99

Asset Turnover

0.03

Inventory Turnover

0.00

The current PE Ratio of Taysha Gene Therapies is -10.32. Taysha Gene Therapies’s PEG ratio is 0.62.

PE Ratio

-10.32

PS Ratio

258.23

PB Ratio

4.15

Price to FCF

-10.45

Price to Operating Cash Flow

-12.17

PEG Ratio

0.62

In the last 12 months, Taysha Gene Therapies had revenue of 9.77M and earned -109.00M in profits. Earnings per share was -0.34.

Revenue

9.77M

Gross Profit

9.77M

Operating Income

-110.50M

Pretax Income

-109.00M

Net Income

-109.00M

EBITDA

-107.79M

Earnings Per Share (EPS)

-0.34

In the last 12 months, operating cash flow was -132.19M and capital expenditures -3.38M, giving a free cash flow of -135.57M billion.

Operating Cash Flow

-132.19M

Free Cash Flow

-135.57M

Free Cash Flow per Share

-0.37

Taysha Gene Therapies pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-9.63%

Earnings Yield

-9.35%

Beta

2.65

52-Week Price Change

2.11%

50-Day Moving Average

4.77

200-Day Moving Average

5.33

Relative Strength Index (RSI)

43.64

Average Volume (3m)

3.46M

Taysha Gene Therapies upcoming earnings date is Nov 10, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 11, 2026

Next Earnings Date

Nov 10, 2026

Ex-Dividend Date

―

Taysha Gene Therapies as a current ratio of 12.23, with Debt / Equity ratio of 7.36%

Current Ratio

12.23

Quick Ratio

12.23

Debt to Market Cap

0.01

Net Debt to EBITDA

2.80

Interest Coverage Ratio

-1753.94

In the past 12 months, Taysha Gene Therapies has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Taysha Gene Therapies EV to EBITDA ratio is -6.77, with an EV/FCF ratio of -7.44.

EV to Sales

183.89

EV to EBITDA

-6.77

EV to Free Cash Flow

-7.44

EV to Operating Cash Flow

-7.63

Taysha Gene Therapies has $455.41M in cash and marketable securities with $55.55M in debt, giving a net cash position of $399.86M billion.

Cash & Marketable Securities

$455.41M

Total Debt

$55.55M

Net Cash

$399.86M

Net Cash Per Share

$1.23

Tangible Book Value Per Share

$1.05

Gross margin is 83.96%, with operating margin of -2792.32%, and net profit margin of -2728.04%.

Gross Margin

83.96%

Operating Margin

-2792.32%

Pretax Margin

-2728.04%

Net Profit Margin

-2728.04%

EBITDA Margin

-2714.33%

EBIT Margin

-2735.68%

The average price target for Taysha Gene Therapies is $14.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$14.00

Price Target Upside

221.10% Upside

Analyst Consensus

Strong Buy

Analyst Count

8

Revenue Growth Forecast

-32.27%

EPS Growth Forecast

-21.09%

Smart Score

5

AI Score

50